Rockville, MD — November 4, 2025 — Leads & Copy —Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) announced that results from clinical studies of its drug olverembatinib (HQP1351) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting. This marks the eighth consecutive year that data on olverembatinib has been selected for the ASH Annual Meeting. This year, multiple clinical and preclinical studies on three of the company’s investigational drug candidates (olverembatinib, lisaftoclax and APG-5918) have been selected for presentations at the ASH Annual Meeting.
Ascentage Pharma will release the first dataset from the global Phase III study (POLARIS-1) of olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company will also report 4-year follow-up data from a Phase II study of olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP), and updated data on olverembatinib in the second-line treatment of patients with non-T315I-mutant CML-CP.
The ASH Annual Meeting aggregates the latest scientific research on hematologic diseases and will take place December 6-9, 2025, in Orlando, Florida.
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, noted that olverembatinib is currently being evaluated in three global Phase III studies. The company will continue to accelerate its clinical development programs to bring more treatment options to patients.
An overview of presentations featuring Ascentage Pharma’s drug candidates at ASH 2025:
- Oral Presentation
- Lisaftoclax（APG-2575）Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis)Abstract#88
- Poster Presentation
- Lisaftoclax（APG-2575）Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignanciesAbstract#1641
- Olverembatinib（HQP1351）Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)Abstract#1574
- Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutationsAbstract#3788
- Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)Abstract#3782
- Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangementAbstract#1979
- Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice reportAbstract#1999
- The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trialAbstract#3779
- Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapyAbstract#5561
- APG-5918Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)Abstract#1528
- Abstract Only
- Olverembatinib（HQP1351）Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 studyAbstract#442
- Lisaftoclax （APG-2575）BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomesAbstract#3304
Contacts:
Hogan Wan, Head of IR and Strategy, Ascentage Pharma, Hogan.Wan@ascentage.com, +86 512 85557777
Stephanie Carrington, ICR Healthcare, AscentageIR@icrhealthcare.com, +1 (646) 277-1282
Jon Yu, ICR Healthcare, AscentagePR@icrhealthcare.com, +1 (646) 677-1855
Source: Ascentage Pharma
